| Paul Hudson |
Paul Hudson's current job(s) include being the Chief Executive Officer & Director at Sanofi and the Chairman at Novartis Pharma KK. Mr. Hudson's former job(s) include being the Chief Executive Officer at Novartis Pharmaceuticals Corp., the Chief Executive Officer & Director at Sanofi Clir SNC, the President & Director at AstraZeneca KK, the President-AstraZeneca US & EVP-North America at AstraZeneca PLC, a Member-Executive Committee at Novartis AG, the President at AstraZéneca Farmacéutica Spain SA, and the Head-Global Marketing at Schering Plough Holdings France SAS. Mr. Hudson's education history includes completing an undergraduate degree at Manchester Metropolitan University. |
| Madeleine Roach |
Madeleine Roach is currently working as the Executive Vice President-Business Operations at Sanofi. Prior to this, she worked at AstraZeneca GmbH as the Head-Global Finance Services Asia Pacific. Ms. Roach completed her undergraduate degree at the University of London. |
| Jean-Baptiste Chasseloup de Chatillon |
Jean-Baptiste Chasseloup de Chatillon is a French businessperson who has been at the head of 5 different companies. Currently, he is Chief Financial Officer & Executive Vice President at Sanofi. He is also Chief Financial & Information Officer at Fondation PSA Peugeot Citroën, Associate Manager at Peugeot Media Production SNC and Member of City on the Move Institute and on the board of 9 other companies.
In the past Mr. Chasseloup de Chatillon held the position of Chairman at Asm Auto Sud Marche SAS, Chairman for Banque PSA Finance SA, Chairman-Supervisory Board for Peugeot Finance International NV, Chairman for Mister Auto SAS, Vice Chairman & Chief Executive Officer at Stellantis International SA, Chief Financial Officer & EVP-Information Systems at Peugeot SA, Imports Director-Europe at Automobiles Citroën SA and Managing Director at Citroën Belux SA.
He received an undergraduate degree from Université Paris Dauphine-PSL and an undergraduate degree from the University of Lancaster. |
| Dietmar P. Berger |
Dietmar P. Berger is currently the Chief Medical Officer & Global Head-Development at Sanofi since 2019. Prior to this, he worked as the Vice President-Clinical Hematology & Oncology at Genentech, Inc. from 2011 to 2018. He also served as the Head-Clinical Research Centre at The Scripps Research Institute and Universitätsklinikum Freiburg. In 2018, he was the Global Head-Research & Development at Atara Biotherapeutics, Inc. Dr. Berger received his graduate and doctorate degrees from the University of Freiburg. |
| Houman Ashrafian |
Houman Ashrafian is the founder of Heart Metabolics Ltd. (founded in 2014), HMBL Ltd. (founded in 2004), and TRex Bio Ltd. (founded in 2018). Dr. Ashrafian was also the founder of Dualitas Ltd., Catamaran Bio, Inc., Weatherden Ltd., Sitryx Therapeutics Ltd., Alchemab Therapeutics Ltd., Mestag Therapeutics Ltd., Enara Bio Ltd. Dr. Ashrafian's current job(s) included being a Director at Ervaxx Ltd. (since 2016), Zarodex Therapeutics Ltd. (since 2017), Cellinta Ltd. (since 2020), Cybele Therapeutics Ltd. (since 2019), and a Scientific Advisor at SV Health Investors LLP (since 2016). Dr. Ashrafian is also the Managing Partner at SV Health Managers LLP (since 2016). Additionally, Dr. Ashrafian will be the Executive VP, Head-Research & Development at Sanofi starting in 2023. Dr. Ashrafian's former job(s) include being the Chairman of Therini Bio, Inc., a Director at Imbria Pharmaceuticals, Inc., and a Director at Prilenia Therapeutics BV. Dr. Ashrafian's education includes an undergraduate degree from the University of Oxford in 1999, a doctorate degree from the University of Oxford in 2009, and undergraduate and graduate degrees from the University of Cambridge. |
| Nestle Frank |
Nestle Frank is currently working as the Chief Scientific Officer & Global Head-Research at Sanofi since 2020. Prior to this, Dr. Frank worked at Kiadis Pharma NV as a Member-Supervisory Board. |
| Raj Verma |
Raj Verma has a current job as the Chief Diversity, Culture & Experience Officer at Sanofi. |
| Emmanuel Frenehard |
Emmanuel Frenehard is currently the Chief Digital Officer & Executive Vice President at Sanofi. He has a graduate degree from Institut Supérieur de Gestion and an undergraduate degree from EBS Universität für Wirtschaft und Recht gGmbH. |
| François-Xavier Michel Marie Roger |
François-Xavier Michel Marie Roger is currently a Member at Les Prés Fleuris-Stiftung and the Chief Financial Officer at Sanofi. Previously, he held positions such as Director at Britannia Industries Ltd., Comvik International (Vietnam) AB, Nestle Health Science SA, Hoechst Marion Roussel SA de CV, and Sandoz AG. He also served as the Chief Financial Officer & Director at Takeda Pharmaceutical Co., Ltd. from 2014 to 2015. In addition, he was a Non-Executive Director at Sandoz Group AG from 2023 to 2024. Mr. Roger has also worked as the Chief Financial Officer & Senior Executive VP at Millicom International Cellular SA and as the Vice President-Corporate Finance at Danone SA. He has held positions such as Senior Controller at Roussel Uclaf SA and Vice President-Finance at Aventis Pharma Japan. Mr. Roger has a Master's in Business Administration from The Ohio State University and a graduate degree from Audencia. |
| Natalie Bickford |
Natalie Bickford is currently the Chairman of Women 1st Ltd., Director-Kronos Workforce Institute at Kronos, Inc., Chief People Officer & Executive Vice President at Sanofi, and Member-Governors Board at Bryanston School, Inc. She previously worked as Deputy Chairman at People 1st, Director-Group Human Resources at Merlin Entertainments Plc, Director-Human Resources at Sodexho Ltd., and Manager at Barclays PLC. She was also a Member of the Women's Leadership Group at The Prince's Trust. Ms. Bickford received an undergraduate degree from the University of Warwick. |
| Serge Weinberg |
Founder of Weinberg Capital Partners SAS and Institut du Cerveau et de la Moelle Épinière, Serge Weinberg is a French businessperson who has been at the head of 19 different companies and presently holds the position of CEO at Weinberg Capital Partners SAS. Mr. Weinberg is also on the board of Sanofi (former Chairman), Kering SA, Piasa SA (former Chairman) and AFEPT and Member of Council on Foreign Relations, Inc., Manager at Maremma and Manager of Alret.
He previously occupied the position of Chairman & Chief Executive Officer at Rexel SA, Chairman for Accor SA, Director at VL Holding (France), Chairman for Financière Piasa SAS, Chairman of Piasa Holding SAS, Chairman-Supervisory Board at Financière Climater SAS, Chairman of Maremma SASU, Chairman-Supervisory Board for Financière Tess SAS, Chairman for CORUM Vermögensverwaltung AG, Chairman-Supervisory Board for Tess SAS, Chief Executive Officer & Director at Pallas Finance, Chairman-Management Board at Kering SA, President-CFAO at Pinault SARL, Manager of Adoval, Chairman & Chief Executive Officer of Havas Tourisme, Chairman at Montres Corum SARL, President for Compagnie Française de L'Afrique Occidentale SA and Deputy General Manager-Finance at France 3 SA.
Serge Weinberg received a graduate degree from Institut d'Études Politiques d'Aix-en-Provence and an undergraduate degree from Ecole Nationale d'Administration. |
| Preethi Sundaram |
Preethi Sundaram is currently the Director-Global Clinical Research at Sanofi and the Chief Strategy Officer at Catalyst Pharmaceuticals, Inc. She has a background in undergraduate studies from the University of Madras and Birla Institute of Technology & Science. She also holds an MBA from London Business School and a doctorate from the University of Anglia Ruskin. |
| Frédéric Oudéa |
Mr. Frédéric Oudéa is an Independent Chairman at Sanofi, a Chairman at Fondation Ecole Polytechnique, a President at Fédération Bancaire Française, a Vice Chairman at Capgemini SE, a Chief Executive Officer at Société Générale SA, an Independent Director at Capgemini Italia SpA and an Independent Director at Capgemini Service SAS. He is on the Board of Directors at Ecole Polytechnique, Capgemini SE, Institut Europlace de Finance, Capgemini Italia SpA and Capgemini Service SAS. Mr. Oudéa was previously employed as a Vice Chairman by Capgemini Technology Services India Ltd., a President by European Banking Federation aisbl, and a Chief Executive Officer & Director by Société Générale SA. He also served on the board at ALD SA and Societe Generale SA (London Branch). He received his undergraduate degree from Ecole Polytechnique and an undergraduate degree from Ecole Nationale d'Administration. |
| Patrick Kron |
Patrick Kron is the founder of Pkc&I SAS, which was founded in 2016. He is currently the Chairman of Imerys SA, a position he has held since 2019. He is also the Independent Chairman of Imerys SA since 2005. Additionally, he serves as an Independent Director at Sanofi since 2014, a Non-Executive Director at Viohalco SA since 2020, and a Director at Gentilly Verdun SNC. Mr. Kron's former positions include Chairman & Chief Executive Officer at Alstom SA from 2003 to 2016, Chief Executive Officer at Vivendi SE from 2005 to 2006, Chief Executive Officer at Imerys SA from 1998 to 2002, Chairman & Chief Executive Officer at FERROPEM SASU from 1988 to 2002, Chairman & Chief Executive Officer at Mersen France Amiens SAS from 1993 to 1997, Chief Executive Officer & Director at GE Power Solutions (Malaysia) Sdn. Bhd., Chairman at Mersen SA from 1993 to 1997, Chairman at Imerys Talc Canada, Inc., Chairman at ALSTOM Resources Management SAS, Director at Bouygues SA, Director at ElvalHalcor Hellenic Copper & Aluminium Industry SA, Director at Association Française des Entreprises Privées, Director at General Electric UK Holdings Ltd., Managing Director & Director at Alstom Asia Pte Ltd., Independent Director at Holcim Ltd., Director at Halcor Metal Works SA, Manager-Food & Health Care Packaging Sector at Pechiney SA, Member-Supervisory Board at Segula Technologies SA, and Vice President at Les Arts Florissants from 2013 to 2015. He was also the Chief Operating Officer at American National Can Corp from 1995 to 1997. Mr. Kron's education includes an undergraduate degree from Ecole Polytechnique and an undergraduate degree from École Nationale Supérieure des Mines de Paris. |
| Fabienne Lecorvaisier |
Fabienne Lecorvaisier is currently the Chairman at Air Liquide USA LLC. She is also an Independent Director at Sanofi, Safran SA, Aqua Lung, Inc., American Air Liquide Holdings, Inc., Air Liquide Eastern Europe SA, and a Member-Supervisory at Wendel SE. Additionally, she holds the position of Executive Vice President at Air Liquide International Corp. In her former roles, Ms. Lecorvaisier served as the Chairman & Chief Executive Officer at Air Liquide Finance SA. She was also the Chairman at Air Liquide USA LLC and a Director at Air Liquide International SA, Société d'Oxygene et d'Acetylene d'Extreme-Orient SA, Air Liquide Japan G.K., Essilor of America, Inc., Association Nationale des Sociétés par Actions, Air Liquide Welding SA, Aqualung International SA, Air Liquide Eastern Europe SA, and Air Liquide France Industries SA. She held the position of Development Director at Essilor Group Canada Ltd. from 1993 to 2001. Ms. Lecorvaisier was a Director at Rexecode Services SA and The Hydrogen Co. SA. She started her career as a Member of the Corporate Finance Department at Société Générale SA from 1985 to 1989 and later served as an Assistant General Manager at Banque du Louvre from 1990 to 1993. She was also an Executive Vice President at Air Liquide SA from 2008 to 2023. Ms. Lecorvaisier obtained her undergraduate degree from Ecole Nationale des Ponts et Chaussées. |
| Emile Voest |
Emile Voest is the founder of the Hartwig Medical Foundation, founded in 2015, where he holds the title of Non-Executive Director. He was also the founder of the Hubrecht Organoid Technology Foundation, founded in 2013, where he held the title of Medical Director from 2013 to 2016. Additionally, Dr. Voest is the founder of the Center For Personalized Cancer Therapy, founded in 2010, where he currently serves as Director. Dr. Voest's current job(s) include being an Independent Director at Sanofi since 2022 and a Professor at the University of Utrecht since 1999. Dr. Voest's former job(s) include being the Director of the European Society for Medical Oncology from 2015 to 2020 and the Executive Medical Director of Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh from 2014 to 2020. Dr. Voest obtained a doctorate degree from the University of Utrecht. |
| Thomas C. Südhof |
Thomas C. Südhof is the founder of Reata Pharmaceuticals, Inc. (2002), Circuit Therapeutics, Inc. (2011), and Neucyte, Inc. (2017). He is also the founder of Recognify Life Sciences, Inc. Dr. Südhof's current jobs include Independent Director at Sanofi (since 2016), Independent Director at CytoDel LLC (since 2021), Member of the Scientific Advisory Board at Simcere Pharmaceutical Group Ltd., Member of The Royal Society (since 2017), Member of the National Academy of Sciences (since 2002), Member of the American Academy of Arts & Sciences (since 2010), Member of the National Academy of Medicine (United States) (since 2007), Member of Deutsche Akademie der Naturforscher Leopoldina eV (since 2015), Professor at Stanford University School of Medicine, Venture Partner at Catalio Capital Management LP, and Member of the Scientific Advisory Board at Jupiter Therapeutics, Inc. He is also a former Independent Director at Abide Therapeutics, Inc. (2019-2020), Member-Neuroscience Review Board at Genentech, Inc. (2013-2016), Assistant Professor at The University of Texas Southwestern Medical Center (1983-2008), and Research Assistant at Max Planck Institute For Biophysical Chemistry (1978-1981). Dr. Südhof received his doctorate from RWTH Aachen University and his undergraduate degree from the University of Gottingen. |
| Rachel Duan |
Rachel Duan is currently an Independent Non-Executive Director at AXA SA, HSBC Holdings Plc, Sanofi, and Adecco Group AG. Previously, she held the position of Senior VP, President & CEO-Global Markets at GE Aerospace from 2019 to 2020. She also served as the Chief Executive Officer at GE (China) Co., Ltd., GE Healthcare (China) Co. Ltd., and Commercial Director at GE Plastics China Ltd. Ms. Duan holds an MBA from the University of Wisconsin and an undergraduate degree from Shanghai International Studies University. |
| Diane D. Souza |
Diane D. Souza is currently the Director at Amica Mutual Insurance Co., Independent Director at Sanofi, and Director at DBP Services of New York IPA, Inc. She previously held positions such as Chief Executive Officer-Specialty Benefits at UnitedHealth Group, Inc., Chief Executive Officer at UnitedHealthcare Specialty Benefits LLC, and Director at Dental Benefit Providers, Inc., Farm Credit East, ACA, Spectera, Inc., Dental Benefit Providers of Illinois, Inc., Unimerica Insurance Co., Unimerica Life Insurance Company of New York, Nevada Pacific Dental, Inc., National Pacific Dental, Inc., Dental Benefit Providers, Spectera of New York, IPA, Inc., and Dental Benefit Providers of California, Inc. She also served as the CFO-Guaranteed Products Business at Aetna, Inc. Diane started her career as an Accountant at Pricewaterhouse LLP from 1979 to 1994. She later became the COO-OptumHealth Specialty Benefits at OptumHealth, Inc. from 2008 to 2014. Additionally, she worked as a Principal at Deloitte, Haskins & Sells (France) from 1980 to 1988. Diane completed her undergraduate degree at the University of Massachusetts. |
| Gilles Schnepp |
Mr. Schnepp is the former chairman and CEO of Legrand SA. Under his leadership from 2006 through 2018, Legrand grew revenue from approximately 3.7 billion euro to 6 billion euro and net profit from 255 million euro to 772 million euro. During this period, Mr. Schnepp broadened Legrand’s product offering from primarily European markets to a global portfolio of electrical and digital infrastructure solutions, drove Legrand’s expansion into the US as well as into emerging markets, including China, Brazil, and India, as well as an acquisition strategy which added approximately $2 billion in revenue. He serves as a director of Saint-Gobain and Sanofi and is a member of the supervisory board of PSA. Mr. Schnepp began his career at Merrill Lynch before serving as Legrand’s deputy chief financial officer and later chief financial officer. He was twice awarded “Manager of the Year†by Challenges magazine and thrice among the “Best 100 CEOs†by Harvard Business Review. Mr. Schnepp is a member of the executive committee of the employer association MEDEF, chairman of the French Federation of Electrical, Electronic and Communication Industries (FIEEC), chairman of the ESG Commission, a recipient of The Order of Légion d’Honneur, and was awarded the National Order of Merit in 2012. Mr. Schnepp attended the HEC Paris. |
| Claudie Haigneré |
Claudie Haigneré is Member of Academie de l'air et de l'espace, Member of Académie des Sciences et Technologies, Member of Académie Des Sciences D'Outre-Mer and Member of Academie des Sports and on the board of 6 other companies.
In her past career she held the position of Chairman for Universcience.fr, Chairman at La Géode, Counselor at European Space Agency (France), Member of International Academy of Astronautics and Member of Académie des Technologies. |
| Antoine Yver |
Antoine Yver's current jobs include being the Executive Vice President & Chairman-Development at Centessa Pharmaceuticals Plc, an Independent Director at Sanofi, and a Director at Spotlight Therapeutics, Inc. Previously, he worked as a Senior Director at Aventis SA from 1990 to 2005, as an Executive Director at Schering-Plough SAS from 2006 to 2009, as a Senior Director at Johnson & Johnson Medical SAS from 2005 to 2006, as the Head-Global Medicines Development at AstraZeneca PLC from 2015 to 2016, and as the EVP, Global Head-Oncology Research and Development at Daiichi Sankyo Co., Ltd. from 2016 to 2021. Dr. Yver obtained his undergraduate and doctorate degrees from Université Paris-Saclay. |
| Carole Gabriella Ferrand |
Carole Gabriella Ferrand is currently the Chairman at Isai Cap Venture, Independent Director at Sanofi, and Director at Capgemini UK Plc. She has previously worked as the Chief Financial Officer at Capgemini Group, Chief Financial Officer & General Secretary at Sony France SA, and Financing Director at Financière Pinault SCA. Ferrand has also served as a Director at various companies including Tallandier Éditions SA, Palazzo Grassi SpA, and Office National d'Etudes et Recherches Aérospatiales. She holds an undergraduate degree from École des Hautes Études Commerciales de Paris. |
| Barbara Lavernos |
Barbara Lavernos is currently the Deputy CEO-Research, Innovation & Technology at L'Oréal SA since 2021. She is also an Independent Director at Sanofi since 2021. Additionally, she holds the position of Director at Lactobio A and Chief Technology, Operations Officer & EVP at L'Oréal Canada, Inc. Her former positions include being a Director at Bpifrance SA and Bpifrance Participations SA. Ms. Lavernos completed her undergraduate degree at École des Hautes Études d’Ingénieur. |
| Lise Kingo |
Lise Kingo's current job(s) include being the Chairman-Leonardo Centre at Imperial College London, Director at Danone SA, Independent Director at Sanofi, Ex-Officio Director at Learning Disabilities Association, Inc. (Minnesota), Member-Supervisory Board at Covestro AG, Member at Prince of Wales, and Member-Supervisory Board at Covestro Deutschland AG. Ms. Kingo's former job(s) include being the Chief Executive Officer & Executive Director at United Nations Global Compact, Deputy Chairman at GN Store Nord A, Chairman at Steno Diabetes Center A, Chairman at Danish Council On Corporate Social Responsibility, Deputy Chairman at Danmarks Naturfredningsforening, Director-Corporate Environmental Affairs at Novozymes A, Independent Director at Sanofi SA, Independent Director at Grieg Star Shipping AS, Director at PRI Association, Independent Director at Aker Horizons ASA, Chief of Staff & Executive Vice President at Novo Nordisk A, Senior Vice President-Stakeholder Relations at Novo Holdings AS (Denmark), and Professor at Vrije Universiteit Amsterdam. Ms. Kingo's education history includes graduating from the University of Bath in 2000, completing undergraduate studies at Copenhagen Business School in 1991, and completing undergraduate studies at the University of Aarhus in 1986. |
| Emmanuel Andre Marie Babeau |
Emmanuel Andre Marie Babeau is currently serving as an Independent Non-Executive Director at Davide Campari-Milano NV, a Director at Schneider Electric (China) Co. Ltd., Schneider Electric Holdings, Inc., Schneider Electric Usa, Inc., Samos Acquisition Co. Ltd., and Carros Sensors Topco Ltd. He is also a Member-Supervisory Board at Aster Capital Partners SAS and a Managing Partner at Sci Getij. In 2020, he became the Chief Financial Officer at Philip Morris International, Inc. Additionally, he serves as a Member-Supervisory Board at Custom Sensors & Technology SAS. In his former roles, Babeau served as the Deputy Chief Executive Officer at Pernod Ricard SA from 1993 to 2009. He then joined Schneider Electric SE as the Deputy Chief Executive Officer-Finance & Legal from 2009 to 2020. He also held the position of Vice Chairman at Aveva Group Ltd. (United Kingdom) from 2018 to 2020. Babeau has served as an Independent Director at Sodexo SA from 2016 to 2021 and as a Director at Invensys Ltd. from 2014 to 2018. He has held various directorial positions at Telvent GIT SA, Sanofi, AVEVA Solutions Ltd., Schneider Electric France SAS, Schneider Electric Industries SAS, Schneider Electric Taiwan Co. Ltd., Carros Sensors Holdco Ltd., Transformateurs SAS, Schneider Electric Energy Access SAS, Schneider SA, Schneider Electric Ltd., and Innovista Sensors SAS. Babeau completed his undergraduate degree at ESCP Europe Campus Paris in 1989. |
